{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:19:22Z","timestamp":1773832762178,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03438-7","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:25:34Z","timestamp":1769498734000},"page":"935-947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient and Physician Experiences in Immune Thrombocytopenia"],"prefix":"10.1007","volume":"43","author":[{"given":"Andrew","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy","family":"Fassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Pallagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2614-1605","authenticated-orcid":false,"given":"Sandhya R.","family":"Panch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"11","key":"3438_CR1","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"issue":"1","key":"3438_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/asheducation-2018.1.405","volume":"2018","author":"JM Despotovic","year":"2018","unstructured":"Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018;2018(1):405\u201311.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"3438_CR3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1365-2141.2010.08176.x","volume":"149","author":"M Yong","year":"2010","unstructured":"Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149(6):855\u201364.","journal-title":"Br J Haematol"},{"issue":"3","key":"3438_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","volume":"94","author":"H Frederiksen","year":"1999","unstructured":"Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909\u201313.","journal-title":"Blood"},{"key":"3438_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1182\/asheducation.V2012.1.191.3798260","volume":"2012","author":"R Stasi","year":"2012","unstructured":"Stasi R. How to approach thrombocytopenia. Hematol Am Soc Hematol Educ Program. 2012;2012:191\u20137.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3438_CR6","unstructured":"Post-transfusion purpura (PTP) Australian Red Cross Lifeblood2021\u20132025"},{"issue":"23","key":"3438_CR7","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366.","journal-title":"Blood Adv"},{"issue":"22","key":"3438_CR8","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780\u2013817.","journal-title":"Blood Adv"},{"issue":"2","key":"3438_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/ajh.26045","volume":"96","author":"N Cooper","year":"2021","unstructured":"Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) world impact survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188\u201398.","journal-title":"Am J Hematol"},{"key":"3438_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111827","volume":"131","author":"MA Nilforoushzadeh","year":"2024","unstructured":"Nilforoushzadeh MA, Heidari N, Heidari A, et al. The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review. Int Immunopharmacol. 2024;131:111827.","journal-title":"Int Immunopharmacol"},{"key":"3438_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051004","author":"S Audia","year":"2021","unstructured":"Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10051004.","journal-title":"J Clin Med"},{"key":"3438_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101222","volume":"67","author":"JWSA Semple","year":"2024","unstructured":"Semple JWSA, Cooper N, Saad H, Mytych DT, Chea LS, Newland A. Immune thrombocytopenia: pathophysiology and impacts of Romiplostim treatment. Blood Rev. 2024;67:101222.","journal-title":"Blood Rev"},{"key":"3438_CR13","doi-asserted-by":"publisher","first-page":"103677","DOI":"10.1016\/j.autrev.2024.103677","volume":"12","author":"Q Li","year":"2024","unstructured":"Li Q, Marcoux G, Hu Y, Rebetz J, Guo L, Semple E, et al. Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP). Autoimmun Rev. 2024;12:103677.","journal-title":"Autoimmun Rev"},{"issue":"26","key":"3438_CR14","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","volume":"113","author":"DB Cines","year":"2009","unstructured":"Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511\u201321.","journal-title":"Blood"},{"issue":"6","key":"3438_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3949\/ccjm.78gr.10005","volume":"78","author":"K McCrae","year":"2011","unstructured":"McCrae K. Immune thrombocytopenia: no longer \u201cidiopathic.\u201d Cleve Clin J Med. 2011;78(6):358\u201373.","journal-title":"Cleve Clin J Med"},{"issue":"11","key":"3438_CR16","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","volume":"160","author":"YC Cohen","year":"2000","unstructured":"Cohen YC, Djulbegovic B, Shamai-Leibowitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630\u20138.","journal-title":"Arch Intern Med"},{"issue":"13","key":"3438_CR17","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1182\/blood-2010-10-312819","volume":"117","author":"M N\u00f8rgaard","year":"2011","unstructured":"N\u00f8rgaard M, Jensen A, Engebjerg MC, Farkas DK, Thomsen RW, Cha S, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood. 2011;117(13):3514\u201320.","journal-title":"Blood"},{"issue":"4","key":"3438_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/ejh.12777","volume":"97","author":"IU Doobaree","year":"2016","unstructured":"Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016;97(4):321\u201330.","journal-title":"Eur J Haematol"},{"key":"3438_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211010875","volume":"12","author":"N Cooper","year":"2021","unstructured":"Cooper N, Altomare I, Thomas MR, et al. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther Adv Hematol. 2021;12:20406207211010875.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"3438_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.26036","volume":"96","author":"N Cooper","year":"2021","unstructured":"Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, et al. Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199\u2013207.","journal-title":"Am J Hematol"},{"issue":"5","key":"3438_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1600-0609.2011.01587.x","volume":"86","author":"JL Newton","year":"2011","unstructured":"Newton JL, Reese JA, Watson SI, et al. Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2011;86(5):420\u20139.","journal-title":"Eur J Haematol"},{"issue":"4","key":"3438_CR22","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1055\/s-0042-1758546","volume":"6","author":"WEM van Dijk","year":"2022","unstructured":"van Dijk WEM, van der Nap- Vlist MM, Knoop H, Schutgens REG. Possible targets to reduce fatigue in chronic immune thrombocytopenia patients - an explorative study. TH Open. 2022;6(4):e387\u201395.","journal-title":"TH Open"},{"issue":"24","key":"3438_CR23","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1182\/blood.2024027336","volume":"145","author":"DJ Kuter","year":"2025","unstructured":"Kuter DJ, Ghanima W, Cooper N, Liebman HA, Zhang L, Hu Y, et al. Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood. 2025;145(24):2914\u201326.","journal-title":"Blood"},{"issue":"13","key":"3438_CR24","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/bloodadvances.2023012541","volume":"8","author":"CE Neunert","year":"2024","unstructured":"Neunert CE, Arnold DM, Grace RF, Kuhne T, McCrae KR, Terrell DR. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. Blood Adv. 2024;8(13):3578\u201382.","journal-title":"Blood Adv"},{"key":"3438_CR25","unstructured":"WAYRILZ. Prescribing information. Genzyme Corporation."},{"issue":"20","key":"3438_CR26","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood.2021010968","volume":"137","author":"W Ghanima","year":"2021","unstructured":"Ghanima W, Gernsheimer T, Kuter DJ. How i treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood. 2021;137(20):2736\u201344.","journal-title":"Blood"},{"issue":"6","key":"3438_CR27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/ajh.25092","volume":"93","author":"A Cuker","year":"2018","unstructured":"Cuker A. Transitioning patients with immune thrombocytopenia to second-line therapy: challenges and best practices. Am J Hematol. 2018;93(6):816\u201323.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"3438_CR28","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1182\/blood-2023-188527","volume":"142","author":"JB Bussel","year":"2023","unstructured":"Bussel JB, Cooper N, Ghanima W, et al. The lack of tolerable treatments options that can induce durable responses without fear of relapse after discontinuation represents a significant unmet need for patients (Pts) with immune thrombocytopenia (ITP): results from the ITP world impact survey (I-WISh) 2.0. Blood. 2023;142(Supplement 1):1212.","journal-title":"Blood"},{"key":"3438_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070779","author":"ME Mingot-Castellano","year":"2022","unstructured":"Mingot-Castellano ME, Bastida JM, Caballero-Navarro G, Entrena Ure\u00f1a L, Gonz\u00e1lez-L\u00f3pez TJ, Gonz\u00e1lez-Porras JR, et al. Novel therapies to address unmet needs in ITP. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15070779.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"3438_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","volume":"104","author":"W Ghanima","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112\u201323.","journal-title":"Haematologica"},{"key":"3438_CR31","unstructured":"DOPTELET. Prescribing information. Sobi, Inc."},{"key":"3438_CR32","unstructured":"PROMACTA. Prescribing information. Novartis Pharmaceuticals Corporation."},{"key":"3438_CR33","unstructured":"Nplate. Prescribing information. Amgen Inc."},{"key":"3438_CR34","doi-asserted-by":"publisher","first-page":"204062071984173","DOI":"10.1177\/2040620719841735","volume":"10","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"3438_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/09537104.2020.1745168","volume":"32","author":"S Birocchi","year":"2021","unstructured":"Birocchi S, Podda GM, Manzoni M, Casazza G, Cattaneo M. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets. 2021;32(2):216\u201326.","journal-title":"Platelets"},{"issue":"23","key":"3438_CR36","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1182\/blood.2023020243","volume":"141","author":"KM Sanfilippo","year":"2023","unstructured":"Sanfilippo KM, Cuker A. TPO-RAs and ITP remission: cause or coincidence? Blood. 2023;141(23):2790\u20131.","journal-title":"Blood"},{"issue":"23","key":"3438_CR37","first-page":"2867","volume":"141","author":"S Guillet","year":"2023","unstructured":"Guillet S, Crickx E, Azzaoui I, et al. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study. Blood. 2023;141(23):2867\u201377.","journal-title":"Blood"},{"issue":"6","key":"3438_CR38","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","volume":"104","author":"E Lucchini","year":"2019","unstructured":"Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124\u201335.","journal-title":"Haematologica"},{"issue":"9978","key":"3438_CR39","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","volume":"385","author":"W Ghanima","year":"2015","unstructured":"Ghanima W, Khelif A, Waage A, Michel M, Tj\u00f8nnfjord GE, Romdhan NB, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653\u201361.","journal-title":"Lancet"},{"issue":"2","key":"3438_CR40","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","volume":"2","author":"S Chugh","year":"2015","unstructured":"Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75-81.","journal-title":"Lancet Haematol"},{"issue":"7","key":"3438_CR41","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, Mayer J, Treli\u0144ski J, Homenda W, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921\u201330.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"3438_CR42","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1182\/blood-2018-99-110482","volume":"132","author":"A-M Duliege","year":"2018","unstructured":"Duliege A-M, Arnold DM, Boccia R, Boxer M, Cooper N, Hill QA, et al. Two-year safety and efficacy outcomes with fostamatinib in adult patients with immune thrombocytopenia (ITP): open-label extension to phase 3 trial program. Blood. 2018;132(Supplement 1):736.","journal-title":"Blood"},{"issue":"1","key":"3438_CR43","doi-asserted-by":"publisher","first-page":"2456687","DOI":"10.1080\/16078454.2025.2456687","volume":"30","author":"W Ghanima","year":"2025","unstructured":"Ghanima W, Lucas Boronat FJ, Carrai V, Rackwitz S. Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: a series of four case reports. Hematology. 2025;30(1):2456687.","journal-title":"Hematology"},{"key":"3438_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216294","author":"ME Mingot-Castellano","year":"2024","unstructured":"Mingot-Castellano ME, Garc\u00eda-Donas G, Campos-\u00c1lvarez RM, de Mora MCF, Luis-Navarro J, Dom\u00ednguez-Rodr\u00edguez JF, et al. Platelet responses after tapering and discontinuation of fostamatinib in patients with immune thrombocytopenia: a continuation of the Fostasur study. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13216294.","journal-title":"J Clin Med"},{"issue":"5","key":"3438_CR45","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ajh.25444","volume":"94","author":"JB Bussel","year":"2019","unstructured":"Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94(5):546\u201353.","journal-title":"Am J Hematol"},{"issue":"48","key":"3438_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005098","volume":"95","author":"LH Thai","year":"2016","unstructured":"Thai LH, Mah\u00e9vas M, Roudot-Thoraval F, Limal N, Languille L, Dumas G, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016;95(48):e5098.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"3438_CR47","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","volume":"131","author":"S Chaturvedi","year":"2018","unstructured":"Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172\u201382.","journal-title":"Blood"},{"issue":"4","key":"3438_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tmrv.2022.08.003","volume":"36","author":"D Jiang","year":"2022","unstructured":"Jiang D, Al-Samkari H, Panch SR. Changing paradigms in ITP management: newer tools for an old disease. Transfus Med Rev. 2022;36(4):188\u201394.","journal-title":"Transfus Med Rev"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03438-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:29:21Z","timestamp":1773822561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03438-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3438"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03438-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"27 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Hsu has declared no conflicts of interest. Tammy Fassett participates in the\u00a0Doptellers Ambassador Program. Steve Pallagi is enrolled in the Doptelet Connect program. Sandhya R. Panch has received honoraria and research funding from Sanofi, Sobi, Rigel, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any new studies with human participants or animals performed by any of the authors. The patients provided written informed consent for their clinical details and personal experiences to be shared in this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}